Tabula Rasa HealthCare Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Tabula Rasa HealthCare han disminuido a una tasa media anual de -17.4%, mientras que en la industria Healthcare Services los beneficios crecieron en un 2.8% anualmente. Los ingresos han ido creciendo a una tasa media de 7.8% al año.

Información clave

-17.4%

Tasa de crecimiento de los beneficios

-12.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services	1.7%
Tasa de crecimiento de los ingresos	7.8%
Rentabilidad financiera	n/a
Margen neto	-18.1%
Última actualización de beneficios	30 Jun 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Tabula Rasa HealthCare. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:TRHC Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 23	338	-61	85	11
31 Mar 23	321	-64	82	12
31 Dec 22	300	-77	81	14
30 Sep 22	286	-72	84	14
30 Jun 22	277	-58	72	14
31 Mar 22	268	-59	74	16
31 Dec 21	260	-52	73	15
30 Sep 21	268	-70	76	15
30 Jun 21	271	-80	79	17
31 Mar 21	283	-80	82	16
31 Dec 20	221	-57	62	14
30 Sep 20	293	-57	80	19
30 Jun 20	297	-44	78	20
31 Mar 20	297	-36	80	21
31 Dec 19	285	-32	73	22
30 Sep 19	269	-36	66	20
30 Jun 19	249	-18	58	18
31 Mar 19	221	-40	43	16
31 Dec 18	204	-47	36	12
30 Sep 18	190	-26	33	10
30 Jun 18	169	-30	28	8
31 Mar 18	149	-3	26	7
31 Dec 17	133	13	26	6
30 Sep 17	117	-3	27	5
30 Jun 17	109	-8	25	4
31 Mar 17	102	-7	21	4
31 Dec 16	95	-3	16	4
30 Sep 16	87	4	11	4
30 Jun 16	80	-11	11	4
31 Mar 16	75	-12	10	3
31 Dec 15	70	-13	10	3
30 Sep 15	64	-20	10	2
30 Jun 15	59	-6	9	2
31 Mar 15	53	-5	8	1
31 Dec 14	48	-5	6	2
31 Dec 13	25	-9	5	1

Ingresos de calidad: TRHC actualmente no es rentable.

Margen de beneficios creciente: TRHC actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: TRHC no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 17.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de TRHC en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: TRHC no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare Services (15.4%).

Rentabilidad financiera

Alta ROE: El pasivo de TRHC supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Tabula Rasa HealthCare Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching

Insufficient new directors

Co-Founder recently sold US$2.9m worth of stock

Third quarter 2021 earnings released: US$0.73 loss per share (vs US$0.99 loss in 3Q 2020)

Price target decreased to US$46.71

Is Tabula Rasa HealthCare (NASDAQ:TRHC) A Risky Investment?

Tabula Rasa and Hesperos Receive $1.9 Million National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer's Disease

Chief Operating Officer recently sold US$90k worth of stock

Second quarter 2021 earnings released: US$0.91 loss per share (vs US$0.66 loss in 2Q 2020)

Tabula Rasa Healthcare, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2021 and Year Ending December 31, 2021

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Desglose de ingresos y gastos
Beta